Additionally, we included 2 more genes to our panel: gonadotropin-releasing hormone receptor (GNRHR), a differentially expressed gene, which is not reported as prognostic, but our previous work showed its possible targetability in cancer, and CD27, which did not meet the fold-change criteria but was reported to have positive prognostic effect in melanoma patients. This evidence concerns the gene CD27 and melanoma.